Opinion|Videos|January 6, 2026
ASCENT-04: Outcomes With Sacituzumab Govitecan Plus Pembrolizumab In First-Line TNBC
Author(s)Laura Huppert, MD
Advertisement
Episodes in this series
Laura Huppert, MD, discusses efficacy and safety outcomes from the phase 3 ASCENT-04 trial, which compared the combination of the antibody-drug conjugate sacituzumab govitecan plus thePD-1 inhibitor pembrolizumab with the standard regimen of pembrolizumab plus chemotherapy in the first-line setting for patients with PD-L1–positive advanced triple-negative breast cancer (TNBC). She also explains the clinical implications of the results on the TNBC treatment paradigm.
Advertisement
Related to this article
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
2
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
3
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
4
Telehealth May Offer a Path to More Equitable Myeloma Transplant Access
5